SubsidieMeestersin silico bio-evolutio - novel AI paradigm for molecular biology
This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.
Projectdetails
Introduction
The success of phage therapies relies on correctly matching a therapeutic phage to a bacterial strain. However, calibration of the therapy recipe may last for years.
Proposed Solution
The presented solution enables acceleration of this process through in silico simulations on an AI platform for in vitro applications. It is capable of:
- Predicting given phage effectiveness against a specific bacteria strain.
- Indicating mutations that increase phage effectiveness.
- Generating explanations for predictions.
Current Process
Currently, this process is performed by wet-lab employees (in vitro). Replacing it with an in silico process will reduce the number of experiments by 90 out of 100, significantly accelerating the process and improving phage therapy quality.
Broader Implications
At the same time, this approach serves as the basis for modern probiotics aimed at microbiome modulation. Additionally, it will enable the dynamic generation of personalized therapies for specific patients. This represents a novel endeavor in the area of molecular biology.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.692.596 |
| Totale projectbegroting | € 2.417.995 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CAMINO SCIENCE SP. Z O.O.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Fast, easy diagnostics for personalised phage therapyVésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours. | EIC Accelerator | € 1.800.000 | 2023 | Details |
BioSim M2M: Molecules to MedicineBioSimulytics' BioSim M2M technology accelerates pharmaceutical R&D by predicting stable crystal structures and binding poses, reducing analysis time from 3 months to 3 weeks. | EIC Accelerator | € 2.499.525 | 2023 | Details |
Fast, easy diagnostics for personalised phage therapy
Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.
BioSim M2M: Molecules to Medicine
BioSimulytics' BioSim M2M technology accelerates pharmaceutical R&D by predicting stable crystal structures and binding poses, reducing analysis time from 3 months to 3 weeks.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered ProphagesPHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine. | ERC Starting... | € 1.500.000 | 2025 | Details |
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPRThis project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies. | ERC Consolid... | € 1.999.780 | 2022 | Details |
Phage infection of bacterial biofilmThis project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections. | ERC Consolid... | € 1.992.976 | 2023 | Details |
Phage co-infection: a missing link in deciphering phage co-evolutionary dynamicsMULTIPHAGE aims to revolutionize our understanding of phage genome evolution by investigating co-infection dynamics through innovative omics methods and structural phylogeny. | ERC Starting... | € 1.499.401 | 2024 | Details |
Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugsThis project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies. | ERC Starting... | € 1.496.500 | 2022 | Details |
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR
This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.
Phage infection of bacterial biofilm
This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.
Phage co-infection: a missing link in deciphering phage co-evolutionary dynamics
MULTIPHAGE aims to revolutionize our understanding of phage genome evolution by investigating co-infection dynamics through innovative omics methods and structural phylogeny.
Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs
This project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies.